keyword
MENU ▼
Read by QxMD icon Read
search

Menopausal symptoms

keyword
https://www.readbyqxmd.com/read/28426619/committee-opinion-no-698-hormone-therapy-in-primary-ovarian-insufficiency
#1
(no author information available yet)
Primary ovarian insufficiency describes a spectrum of declining ovarian function and reduced fecundity due to a premature decrease in initial follicle number, an increase in follicle destruction, or poor follicular response to gonadotropins. The sequelae of primary ovarian insufficiency include vasomotor symptoms, urogenital atrophy, osteoporosis and fracture, cardiovascular disease, and increased all-cause mortality. In women with primary ovarian insufficiency, systemic hormone therapy (HT) is an effective approach to treat the symptoms of hypoestrogenism and mitigate long-term health risks if there are no contraindications to treatment...
May 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28426614/committee-opinion-no-698-summary-hormone-therapy-in-primary-ovarian-insufficiency
#2
(no author information available yet)
Primary ovarian insufficiency describes a spectrum of declining ovarian function and reduced fecundity due to a premature decrease in initial follicle number, an increase in follicle destruction, or poor follicular response to gonadotropins. The sequelae of primary ovarian insufficiency include vasomotor symptoms, urogenital atrophy, osteoporosis and fracture, cardiovascular disease, and increased all-cause mortality. In women with primary ovarian insufficiency, systemic hormone therapy (HT) is an effective approach to treat the symptoms of hypoestrogenism and mitigate long-term health risks if there are no contraindications to treatment...
May 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28422418/factors-associated-with-mucosal-dryness-in-multiple-regions-and-skin-a-web-based-study-in-women
#3
Kayoko Ito, Kiyoshi Takamatsu, Kaname Nohno, Aki Sugano, Saori Funayama, Kouji Katsura, Noboru Kaneko, Mariko Ogawa, Jukka H Meurman, Makoto Inoue
AIM: We hypothesized that feeling mucosal dryness in one body region and the skin may be associated with dryness in other regions and that there are common background factors for dryness. In an earlier web-based survey, we reported prevalence figures of dry eyes, nose, mouth, skin, and vagina. In the present study, additional analyses were made to investigate the factors associated with dryness in each region, and simultaneous dryness in multiple regions. METHODS: A web-based questionnaire was completed by 310 Japanese women...
April 19, 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/28420227/efficacy-and-tolerability-of-a-plant-based-multi-component-cream-ginetrox%C3%A2-in-vulvovaginal-disorders-of-the-genitourinary-syndrome-during-menopause
#4
Roberto Marrai, Giovanni Lissi, Stefano Togni, Giada Maramaldi, Marco Barbara, Luca Giacomelli
BACKGROUND: Genitourinary syndrome of menopause (GSM) is a symptomatic condition including vaginal dryness, irritation, dyspareunia and recurrent urinary tract infections which affects 40-54% of post-menopausal women. Although several estrogen-based therapies are available, it is generally preferable to avoid hormonal therapy, particularly in women with mild symptoms or at risk for estrogen-responsive neoplasia. Therefore, the most common treatment options are over-the-counter vaginal creams for symptomatic relief...
June 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28419911/safety-and-long-term-efficacy-of-fractional-co2-laser-treatment-in-women-suffering-from-genitourinary-syndrome-of-menopause
#5
Fariba Behnia-Willison, Sara Sarraf, Joseph Miller, Behrang Mohamadi, Alison S Care, Alan Lam, Nadia Willison, Leila Behnia, Stefano Salvatore
OBJECTIVES: To evaluate the safety and long-term efficacy of fractional CO2 laser treatment in reducing the severity of symptoms of genitourinary syndrome of menopause (GSM) in menopausal women. STUDY DESIGN: 102 women presenting with symptomatic GSM were treated with the fractional CO2 laser (MonaLisa Touch, DEKA) system across a series of treatments delivered at intervals of six or more weeks. The Australian Pelvic Floor Questionnaire was used to gather data on sexual function and side-effects at three time-points across the study period (prospective panel design study)...
April 2, 2017: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/28411144/management-of-sexuality-intimacy-and-menopause-symptoms-sims-in-ovarian-cancer-patients-expert-review
#6
REVIEW
Margaret Whicker, Jonathan Black, Gary Altwerger, Gulden Menderes, Jacqueline Feinberg, Elena Ratner
Issues of sexuality, intimacy, and early menopause significantly impact the quality of life of patients following the diagnosis and treatment of ovarian cancer. These are undertreated problems. Successful treatment requires the provider's awareness of the problem, ability to identify it, and willingness to treat it. Unfortunately many providers do not address these issues in the pre-treatment or perioperative period. Furthermore, patients do not often alert their providers to their symptoms. While systemic hormone therapy may improve many of the issues, they are not appropriate for all patients given their action on estrogen receptors...
April 11, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28409538/prevalence-and-predictors-of-severe-menopause-symptoms-among-hiv-positive-and-negative-nigerian-women
#7
Patricia A Agaba, Seema T Meloni, Halima M Sule, Amaka N Ocheke, Emmanuel I Agaba, John A Idoko, Phyllis J Kanki
We compared the prevalence of menopause symptoms between women living with HIV to their HIV-negative peers and determined predictors of severe menopause symptoms in Jos, Nigeria. This descriptive cross-sectional study included 714 women aged 40-80 years. We compared prevalence and severity of menopause symptoms using the menopause rating scale (MRS). Logistic regression analysis was used to determine the predictors of severe symptoms. Six-hundred and seven (85.0%) were HIV-positive, with a mean duration of infection of 5...
January 1, 2017: International Journal of STD & AIDS
https://www.readbyqxmd.com/read/28408389/bazedoxifene-for-hrt
#8
(no author information available yet)
Duavive (Pfizer) is a modified-release formulation of conjugated oestrogens plus bazedoxifene acetate (a selective oestrogen receptor modulator). It is licensed for treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus for whom treatment with progestogen-containing therapy is not appropriate.(1,2) It was licensed by the European Medicines Agency (EMA) in 2014 and launched in the UK in July 2016.(1,3) Here, we review the evidence on efficacy and safety of conjugated oestrogens/bazedoxifene and consider its place in the management of symptoms associated with the menopause...
April 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28399790/obstacles-to-the-discussion-of-sexual-problems-in-menopausal-women-a-qualitative-study-of-healthcare-providers
#9
Masoumeh Ghazanfarpour, Talat Khadivzadeh, Robab Latifnejad Roudsari, Seyed Mohammad Mehdi Hazavehei
The aim of this study was to explore issues that challenge menopausal women in discussions of their sexual problems with a physician. This was done from the perspective of healthcare providers. In a descriptive exploratory qualitative study, using a semi-structured interview and purposive sampling, a sample set of 12 midwives and 13 general practitioners aged 25-70 years were selected in order to elicit meaning behind their experiences about the subject under study. Data analysis was carried out using qualitative content analysis...
April 11, 2017: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28399661/hormone-therapy-for-premature-ovarian-insufficiency-patients-with-malignant-hematologic-diseases
#10
X Yang, C Wang, X He, J Wei, Y Wang, X Li, L-P Xu
OBJECTIVES: The current usage of hormone therapy (HT) among perimenopausal women is low in China, especial in women with premature ovarian insufficiency (POI) with malignant hematologic diseases. This study investigated the efficacy and safety of HT in POI patients with malignant hematologic diseases who have received myeloablative chemotherapy and hemopoietic stem cell transplantation (HSCT). METHODS: Patients who had POI after myeloablative chemotherapy and HSCT for malignant hematologic diseases were enrolled...
April 11, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28399093/-the-differential-diagnosis-and-treatment-of-depressive-disorders-in-climacteric-transition
#11
N A Tyuvina, V V Balabanova, E O Voronina
AIM: To study clinical symptoms of menopause depression, develop differential diagnostic criteria and consider treatment aspects. MATERIAL AND METHODS: One hundred and fifty women, aged 41-65 years, with mental disorders developed in different periods of menopause (perimenopause, menopause and post menopause) were studied. RESULTS AND CONCLUSION: Four types of depression were diagnosed: climacteric (n=46), psychogenic (n=35), endogenic (n=42) and involutional (n=27)...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28398024/gonadotropin-releasing-hormone-analogues-for-the-prevention-of-chemotherapy-induced-premature-ovarian-failure-in-breast-cancer-patients
#12
Benedetta Conte, Lucia Del Mastro
Since the survival of patients with cancer has significantly improved, chemotherapy-related premature ovarian failure (POF) in young cancer survivors has become a major issue in oncology. POF is associated with several health-related negative consequences, including menopausal symptoms, increased risk of cardiovascular diseases, osteoporosis, sexual disfunction, and infertility1-5. According to the major international guidelines, embryo/oocyte cryopreservation are the standard procedures for fertility preservation in young cancer women6,7...
April 10, 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28395337/effects-of-vaginal-conjugated-equine-estrogens-and-ospemifene-on-the-rat-vaginal-wall-and-lower-urinary-tract
#13
P Antonio Maldonado, T Ignacio Montoya, Jesus F Acevedo, Patrick W Keller, R Ann Word
Although the positive effects of vaginal estrogens and the selective estrogen receptor modulator, ospemifene (OS), on the vaginal epithelium are well recognized, less is known regarding the effects of these therapies on the lower urinary tract or vaginal muscularis. Clinical evidence suggests that vaginally administered estrogen may improve overactive bladder-related symptoms. The objective of this study was to compare the effects of OS, vaginal conjugated equine estrogens (CEE), or both on the vaginal wall and lower urinary tract in a rat model of menopause...
January 1, 2017: Biology of Reproduction
https://www.readbyqxmd.com/read/28385352/neurokinin-3-receptor-antagonism-as-a-novel-treatment-for-menopausal-hot-flushes-a-phase-2-randomised-double-blind-placebo-controlled-trial
#14
Julia K Prague, Rachel E Roberts, Alexander N Comninos, Sophie Clarke, Channa N Jayasena, Zachary Nash, Chedie Doyle, Deborah A Papadopoulou, Stephen R Bloom, Pharis Mohideen, Nicholas Panay, Myra S Hunter, Johannes D Veldhuis, Lorraine C Webber, Les Huson, Waljit S Dhillo
BACKGROUND: Hot flushes affect 70% of menopausal women and often severely impact physical, psychosocial, sexual, and overall wellbeing. Hormone replacement therapy is effective but is not without risk. Neurokinin B signalling is increased in menopausal women, and has been implicated as an important mediator of hot flushes. METHODS: This phase 2, randomised, double-blind, placebo-controlled, single-centre, crossover trial assessed the effectiveness of an oral neurokinin 3 receptor antagonist (MLE4901) on menopausal hot flushes...
April 3, 2017: Lancet
https://www.readbyqxmd.com/read/28384829/vaginal-and-urinary-symptoms-of-menopause
#15
Jill Jin
No abstract text is available yet for this article.
April 4, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28382320/female-hormonal-exposures-and-neuromyelitis-optica-symptom-onset-in-a-multicenter-study
#16
Riley Bove, Liene Elsone, Enrique Alvarez, Nadja Borisow, Melissa M Cortez, Farrah J Mateen, Maureen A Mealy, Kerry Mutch, Sean Tobyne, Klemens Ruprecht, Guy Buckle, Michael Levy, Dean M Wingerchuk, Friedemann Paul, Anne H Cross, Brian Weinshenker, Anu Jacob, Eric C Klawiter, Tanuja Chitnis
OBJECTIVE: To study the association between hormonal exposures and disease onset in a cohort of women with neuromyelitis optica spectrum disorder (NMOSD). METHODS: Reproductive history and hormone use were assessed using a standardized reproductive survey administered to women with NMOSD (82% aquaporin-4 antibody positive) at 8 clinical centers. Using multivariable regression, we examined the association between reproductive exposures and age at first symptom onset (FS)...
May 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28381099/oxytocin-stimulates-cell-proliferation-in-vaginal-cell-line-vk2e6e7
#17
Theodora K Kallak, Kerstin Uvnäs-Moberg
Objective During and after menopause, the symptoms of vaginal atrophy cause great discomfort and necessitate effective treatment options. Currently, vaginally applied oxytocin is being investigated as a treatment for the symptoms of vaginal atrophy in postmenopausal women. To clarify the mechanisms behind oxytocins effects on vaginal atrophy, the present study investigated the effects of oxytocin on cell proliferation in the cells of the Vk2E6E7 line, a non-tumour vaginal cell line. The study also compared the effects of oxytocin with those of estradiol (E2)...
March 2017: Post Reproductive Health
https://www.readbyqxmd.com/read/28380486/neurokinin-3-receptor-antagonism-reveals-roles-for-neurokinin-b-in-the-regulation-of-gonadotropin-secretion-and-hot-flashes-in-postmenopausal-women
#18
Karolina Skorupskaite, Jyothis T George, Johannes D Veldhuis, Robert P Millar, Richard A Anderson
OBJECTIVES: Neurokinin B (NKB) and kisspeptin are obligate for normal gonadotropin secretion, and links between GnRH pulsatility and vasomotor symptoms have been proposed. Using a selective NKB receptor (NK3R) antagonist, the role of NKB in the hypergonadotropic state in menopausal women was explored. METHODS: Eleven postmenopausal women were administered the NK3R antagonist MLE4901, 40 mg twice daily orally for 7 days. 10-min blood sampling for 8 h was performed before and on the last day of NK3R antagonist treatment for LH pulsatility analysis with kisspeptin-10 (0...
April 5, 2017: Neuroendocrinology
https://www.readbyqxmd.com/read/28379074/the-menopausal-hot-flush-a-review
#19
D W Sturdee, M S Hunter, P M Maki, P Gupta, J Sassarini, J C Stevenson, M A Lumsden
The hot flush is the most characteristic and often the most distressing symptom of the menopause. It is a unique feature and yet the mechanism and health implications are still not fully understood. This review summarizes some of the current thoughts on factors contributing to flushing, the physiological, vascular and neuroendocrine changes associated with flushing and the possible cardiovascular and other health implications for women experiencing hot flushes. Therapy is not discussed.
April 5, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28375935/estriol-emerging-clinical-benefits
#20
Emad S Ali, Cheyenne Mangold, Alan N Peiris
OBJECTIVE: Estriol is the main estrogen in pregnancy, but has received less attention outside gestation. It is well known that pregnancy has an immunosuppressive effect on many autoimmune diseases such as multiple sclerosis, psoriasis, thyroiditis, uveitis, and rheumatoid arthritis. Emerging evidence indicates that estriol has potential immunomodulatory benefits for many disease states including autoimmune, inflammatory, and neurodegenerative conditions. In this review, we discuss emerging roles for estriol in the treatment of menopausal symptoms, osteoporosis, cancer, hyperlipidemia, vascular disease, and multiple sclerosis...
April 3, 2017: Menopause: the Journal of the North American Menopause Society
keyword
keyword
47383
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"